Not available in the U.S.
Luseogliflozin
LUSEFI
What it isA selective sodium-glucose cotransporter-2 (SGLT2) inhibitor that lowers blood glucose by blocking renal glucose reabsorption in the proximal tubule, driving urinary glucose excretion.
Why this oneApproved in Japan (not the US) for type 2 diabetes, providing insulin-independent glycemic control with modest weight loss and little intrinsic hypoglycemia risk.
What limits itCarries the SGLT2-class cautions—genital mycotic and urinary tract infections, volume depletion/hypotension, and rare euglycemic diabetic ketoacidosis.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning.
Classes and tags
Clinical profile
Mechanism of action: Luseogliflozin ballicule
